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Short communication
A pilot study of megestrol acetate and ibuprofen in the
treatment of cachexia in gastrointestinal cancer
patients
DC McMillan1, P O'Gorman1, KCH Fearon2 and CS McArdle'
'University Department of Surgery, Royal Infirmary, Glasgow G31 2ER; 2University Department of Surgery, Royal Infirmary, Edinburgh EH3 9YW, UK
Summary Advanced gastrointestinal cancer patients with weight loss and an acute-phase response (n = 15) were given megestrol acetate
(480 mg day-') and ibuprofen (1200 mg day-') for 6 weeks. Overall, there was an increase in body weight (P = 0.01) and a reduction in
C-reactive protein concentrations (P = 0.02), with no change in total body water (P= 0.24) over this period. This regimen may be an effective
non-toxic treatment for cancer cachexia and is worthy of further study.
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Cancer cachexia causes distress, loss of independence and reduces
quality and duration of life (Inagaki et al, 1974; Kern and Norton,
1988). It has been shown previously that the administration of
megestrol acetate results in a significant proportion of patients
with advanced breast cancer gaining weight (Tchekmedyian et al,
1986; Parnes et al, 1991). Subsequent randomized, placebo-
controlled studies, including heterogeneous groups of patients
with a spectrum of hormone-insensitive tumours, have demon-
strated that the administration of megestrol acetate can result in
improvements in weight, appetite and quality of life (Loprinzi et
al, 1990; Feliu et al, 1991; Tchemedyian et al, 1992). However, in
similar studies looking at advanced gastrointestinal cancer patients
alone, no significant gain in weight has been documented
(Schmoll et al, 1991; McMillan et al, 1994). It may be that in such
patients simple augmentation of food intake (by stimulating
appetite with megestrol acetate) is unable to overcome the devel-
oping syndrome of cachexia.
Studies in animals and in man suggest that cytokine-mediated
metabolic events (such as the acute-phase response) may
contribute to both the anorexia and the metabolic changes that lead
to weight loss in cancer (Kern and Norton, 1988; Fearon, 1992;
Scott et al, 1996). It is therefore of interest that the majority of
patients with advanced gastrointestinal cancer and weight loss
have an ongoing acute-phase protein response (McMillan et al,
1994), and we have recently demonstrated that the non-steroidal
anti-inflammatory drug, ibuprofen, can reduce not only mediators
of the inflammatory response, such as interleukin-6 and cortisol
(McMillan et al, 1995), but also metabolic end points, such as the
acute-phase protein response (Preston et al, 1995) and resting
energy expenditure (Wigmore et al, 1995).
The aim of the present study was to test, in a small group of
patients with advanced gastrointestinal cancer, the hypothesis that
down-regulating the acute-phase response using ibuprofen and
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perhaps stimulating the appetite using megestrol acetate may be
effective in reversing or halting weight loss.
MATERIALS AND METHODS
Fifteen patients with histologically proven locally advanced or
metastatic gastrointestinal cancer, more than 5% weight loss and
evidence of an acute-phase response (circulating C-reactive
protein concentration > 5 mg 1-') were studied. Three patients had
liver metastases, although none had abnormal liver function tests,
and three patients were on H2-receptor antagonists during the
study. Patients did not have surgery, radiotherapy or chemotherapy
in the 6 weeks before the study or during the study period.
Furthermore, no patient received corticosteroids or non-steroidal
anti-inflammatory drugs other than ibuprofen during the course of
the study. No patient complained of moderate or severe dysphagia
and none had an obvious functional obstruction to food intake.
Baseline measurements of height, weight and total body water
were undertaken. Total body water was measured using a Xitron
4000B bioimpedance spectrum analyser (Xitron Technologies,
San Diego, CA, USA) as described previously (Hannan et al,
1994). Venous blood samples were taken for routine laboratory
measurement of C-reactive protein, albumin, haemoglobin, total
white blood cell count, differential white cell and platelet counts.
Table 1 Characteristics of weight-losing gastrointestinal cancer patients
Age (years) 64 (44-79)
Sex (M/F) 10/5
Body mass index 21 (17-30)
Weight loss (%) 15 (7-32)
Cancer site
Stomach (n) 3
Pancreas (n) 2
Liver (n) 3
Colon (n) 3
Rectum (n) 4
Data given as median and range in brackets.
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Table 2 Weight, total body water and blood values
Baseline 6 weeks P-value
Weight (kg) 53.7 (41.3-83.2) 58.0 (46.0-83.5) 0.01
Total body water (l) 31.7 (24.1-41.7) 29.6 (25.3-49.7) 0.24
Albumin (g l-') 39 (31-46) 40 (30-45) 0.81
C-reactive protein (mg 1-') 40 (6-163) 13 (<5-128) 0.02
Haemoglobin (g l-') 12.0 (9.2-13.8) 11.7 (6.2-13.6) 0.48
WBC count (106 ml-') 7.8 (2.7-12.1) 9.4 (2.8-12.9) 0.51
Neutrophil count (106 ml-') 5.5 (1.6-9-5) 6.3 (1.6-10.4) 0.79
Lymphocyte count (106 ml-') 1.5 (0.5-2.4) 1.4 (0.6-3.0) 0.29
Platelets (106 ml-') 339 (95-544) 287 (121-578) 0.85
Data given as medians and range in brackets.
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Figure 1 Weight gain in gastrointestinal cancer patients after 6 weeks'
treatment with megestrol acetate and ibuprofen
All patients were given both megestrol acetate (480 mg day-',
160 mg t.i.d.) and ibuprofen (1200 mg day-', 400 mg t.i.d.) for 6
weeks and the measurements repeated.
The study was approved by the local ethical committee. All
patients were informed of the purpose and procedure of the study
and all gave written informed consent.
Data are presented as medians and range. Where appropriate,
data were tested for statistical significance using the Wilcoxon
signed rank U-test (Minitab, State College, Philadelphia, USA).
RESULTS
The characteristics of the patients (n = 15) are given in Table 1.
The median weight loss of the patients was 15%.
Weight, total body water and blood values are given in Table 2.
There was a significant increase in weight after 6 weeks of mege-
strol acetate and ibuprofen (P = 0.01), the median weight change
of the group being 1.3 kg (range -2.8 to 6.8 kg). Two of the 15
patients lost weight (1.3 and 2.8 kg), while the other 13 patients
either were weight stable or gained weight (Figures 1 and 2). The
median weight change of these 13 patients was 3.8 kg (range
.
*:
0
0
I
I 0~~~~
I I
50 100
C-reactive protein concentration (mg l-1)
Figure 2 Plot of post-treatment C-reactive protein concentration and the
weight gained after 6 weeks of megestrol acetate and ibuprofen
0.1-6.8 kg). The two non-responsive patients who continued to
lose weight (i.e. those with negative weight gain) had liver and
stomach cancer, had similar supportive care (including pain
control) and did not appear to die sooner than the other patients
studied. Furthermore, these patients were aged 61 and 64 years
and before treatment they had lost 14% and 21% respectively of
their usual body weight and so appeared to be similar to the other
patients studied.
The blood concentrations of albumin, haemoglobin and the
differential white cell count of the patients did not change signifi-
cantly over the 6-week period of the study. However, there was a
significant reduction in circulating C-reactive protein concentra-
tion at 6 weeks compared with the baseline value (P = 0.02).
Furthermore, there was a significant inverse correlation between
the post-treatment C-reactive protein concentration and the weight
gained over the 6-week period (Figure 2, r = -0.5, P = 0.05).
Measurements of total body water, at baseline and at 6 weeks,
were carried out in 11 of the 15 patients (two weight-losing and
nine weight-gaining patients). There was no significant difference
in total body water over the 6-week period.
There was no treatment-related toxicity, gastrointestinal side-
effects or clinically apparent deterioration in glucose tolerance
observed in any of the patients studied.
DISCUSSION
In the present study, there was an overall weight gain (1.3 kg) over
a 6-week period in a small group (n = 15) of weight-losing
gastrointestinal cancer patients given a combination of ibuprofen
and megestrol acetate. This is in contrast to the overall weight loss
(1.7 kg), over 6 weeks, reported in our previous randomized,
placebo-controlled study of megestrol acetate alone in a similar
group of advanced gastrointestinal cancer patients (McMillan et al,
1994). Therefore, it would appear that the addition of ibuprofen
(1200 mg day-') has significantly altered the efficacy of megestrol
acetate in the management of gastrointestinal cancer patients with
weight loss. However, the present study does not rule out the possi-
bility that the effects observed were caused by the ibuprofen alone.
It would appear that the inflammatory response via pro-inflam-
matory cytokines, such as interleukin-6, and the corticosteroids,
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such as cortisol, results in the production of a number of acute-
phase proteins. Given that the exact mechanism by which acute-
phase proteins are elaborated is not clear, we have used an end
product, C-reactive protein, rather than a specific cytokine, as a
marker of the inflammatory response in humans (Pepys and Baltz,
1983; Thompson et al, 1992).
Ibuprofen was given to attenuate the hormone/cytokine-medi-
ated alterations in protein and energy metabolism and as a conse-
quence to normalize the host metabolism. The results of the present
study are consistent with this rationale, since there was an associa-
tion between the reduction in circulating C-reactive protein
concentration and weight gain. Indeed, there was a significant
inverse correlation between the post-treatment C-reactive protein
concentration and weight gain over the 6-week period. These find-
ings support the concept that cytokine-mediated metabolic changes
contribute to the cachexia of patients with gastrointestinal cancer.
Although there was an overall increase in body weight, there
was no significant change in the measured total body water
volumes, and this would suggest that the main tissue gained was
fat. However, the precision of the total body water measurement is
such that our results do not preclude the possibility that there was
an increase in total body water. Indeed, in those patients with most
weight gain, total body water was increased, but this did not
appear to account for the majority of weight gained. Therefore, in
these patients at least a proportion of the tissue gained was likely
to consist of fat, and this is consistent with previous body compo-
sition analyses of cancer patients who have gained weight with
megestrol acetate (Loprinzi et al, 1993).
The results of the present study suggest that weight loss in
patients with gastrointestinal cancer may be halted or reversed
using the combination of megestrol acetate and ibuprofen and is
worthy of further study.
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